Gardasil vaccine

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Human Papillomavirus

Conditions

Human Papillomavirus, HIV-1 Infection

Trial Timeline

Dec 15, 2014 → Jun 30, 2018

NCT ID

NCT01446718

About Gardasil vaccine

Gardasil vaccine is a pre-clinical stage product being developed by Merck for Human Papillomavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT01446718. Target conditions include Human Papillomavirus, HIV-1 Infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01446718	Pre-clinical	Completed	Dec 15, 2014	Jun 30, 2018	Human Papillomavirus
NCT01489527	Pre-clinical	Completed	Sep 1, 2012	Dec 1, 2014	Sexual Transmission of Infection
NCT00727636	Pre-clinical	Completed	Jul 1, 2008	Apr 1, 2011	Inflammatory Bowel Disease

Competing Products

20 competing products in Human Papillomavirus

See all competitors

Product	Company	Stage	Hype Score
Influenza vaccine, split inactivated	Comac Medical	Phase 1	25
CS-8958 + CS-8958 + oseltamivir phosphate	Daiichi Sankyo	Phase 3	77
GSK1265744 30mg + Placebo + GSK1265744 5mg	Shionogi	Phase 2	52
Dolutegravir	Shionogi	Phase 3	77
GSK1349572 + efavirenz	Shionogi	Phase 2	52
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules	Shionogi	Phase 1	33
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mg	Shionogi	Phase 1	33
GSK1349572 (dolutegravir) + raltegravir	Shionogi	Phase 3	77
Ortho-Cyclen + Dolutegravir + Placebo	Shionogi	Phase 1	33
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
dolutegravir	Shionogi	Phase 3	77
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo	Shionogi	Phase 3	77
GSK1349572 + Efavirenz	Shionogi	Phase 1	33
GSK1349572	Shionogi	Phase 1	33
GSK1349572 + Placebo	Shionogi	Phase 2	52
Dolutegravir + Methadone	Shionogi	Phase 1	33
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir Placebo	Shionogi	Phase 3	77
GSK1349572 + Rifampin + Rifabutin	Shionogi	Phase 1	33
DTG + BCV + TVR	Shionogi	Phase 1	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved